TUSC2 immunogene therapy enhances efficacy of immunotherapy and targeted drugs in human non-small cell lung cancer (NSCLC) in humanized mouse models

被引：0
|
作者：
Meraz, Ismail M. [1 ]
Majidi, Mourad [1 ]
Feng, Meng [1 ]
Shao, RuPing [1 ]
Ha, Min Jin [1 ]
Shpall, Elizabeth J. [1 ]
Roth, Jack A. [1 ]
机构：
[1] UT MD Anderson Canc Ctr, Houston, TX USA
来源：
CANCER RESEARCH | 2020年 / 80卷 / 16期
关键词：
D O I：
10.1158/1538-7445.AM2020-4454
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
4454
引用
收藏
页数：2
相关论文
共 50 条
  • [1] TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
    Ismail M. Meraz
    Mourad Majidi
    RuPing Shao
    Feng Meng
    Min Jin Ha
    Elizabeth Shpall
    Jack A. Roth
    Communications Biology, 5
  • [2] TUSC2 immunogene enhances efficacy of chemo-immuno combination on KRAS/LKB1 mutant NSCLC in humanized mouse model
    Meraz, Ismail M.
    Majidi, Mourad
    Shao, RuPing
    Meng, Feng
    Ha, Min Jin
    Shpall, Elizabeth
    Roth, Jack A.
    COMMUNICATIONS BIOLOGY, 2022, 5 (01)
  • [3] TUSC2 downregulates PD-L1 expression in non-small cell lung cancer (NSCLC)
    Cao, Xiaobo
    Zhao, Yang
    Wang, Jing
    Dai, Bingbing
    Gentile, Emanuela
    Lin, Jing
    Pu, Xingxiang
    Ji, Lin
    Wu, Shuhong
    Meraz, Ismail
    Majidi, Mourad
    Roth, Jack A.
    ONCOTARGET, 2017, 8 (64) : 107621 - 107629
  • [4] TUSC2 immunogene therapy enhances checkpoint blockade through increased cytotoxic immune activation in chemo-resistant small cell lung cancer (SCLC) in humanized mice
    Meraz, Ismail M.
    Majidi, Mourad
    Song, Renduo
    Meng, Feng
    Gao, Lihui
    Wang, Qi
    Wang, Jing
    Shpall, Elizabeth
    Berger, Mark
    Kumar, Hemant
    Roth, Jack A.
    MOLECULAR CANCER THERAPEUTICS, 2023, 22 (12)
  • [5] Tumor suppressor TUSC2 immunogene therapy is synergistic with anti-PD1 in lung cancer syngeneic mouse models
    Meraz, Ismail M.
    Majidi, Mourad
    Shao, RuPing
    Feng, Meng
    Cao, Xiaobo
    Rice, David
    Sepesi, Boris
    Ji, Lin
    Roth, Jack
    CANCER RESEARCH, 2017, 77
  • [6] Immunotherapy as a targeted therapy in non-small cell lung cancer
    Rocco, Danilo
    Della Gravara, Luigi
    Avellino, Aniello
    Montesarchio, Vincenzo
    Battiloro, Ciro
    TRANSLATIONAL CANCER RESEARCH, 2019, 8 : S70 - S75
  • [7] TUSC2 immunogene therapy enhances efficacy of chemo-immune combination therapy and induces robust antitumor immunity in KRAS-LKB1 mutant NSCLC in humanized mice.
    Meraz, Ismail M.
    Majidi, Mourad
    Shao, RuPing
    Meng, Feng
    Ha, Min Jin
    Shpall, Elizabeth
    Roth, Jack A.
    CANCER RESEARCH, 2021, 81 (13)
  • [8] Immunotherapy for non-small cell lung cancer (NSCLC)
    Frost, Nikolaj
    Reck, Martin
    INNERE MEDIZIN, 2022, 63 (07): : 709 - 716
  • [9] Targeted Therapy and Immunotherapy in the Treatment of Non-Small Cell Lung Cancer
    Shroff, Girish S.
    de Groot, Patricia M.
    Papadimitrakopoulou, Vassiliki A.
    Truong, Mylene T.
    Carter, Brett W.
    RADIOLOGIC CLINICS OF NORTH AMERICA, 2018, 56 (03) : 485 - +
  • [10] Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
    Moya-Horno, Irene
    Viteri, Santiago
    Karachaliou, Niki
    Rosell, Rafael
    THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY, 2018, 10
12345